NeoGenomics has launched the first FDA-approved PTEN IHC companion diagnostic for prostate adenocarcinoma, enabling identification of patients with PTEN deficiency who may benefit from AstraZeneca’s capivasertib therapy.
The NCCN now recommends comprehensive molecular profiling for all pancreatic cancer patients eligible for therapy, regardless of stage, to better guide targeted treatment and clinical trial enrollment.
The whole-genome test combines data from 7 million genetic markers with clinical risk factors to provide individualized 10-year and lifetime risk assessments.
Fellow Health showcased innovative research, emphasizing mail-in semen testing to enhance prostate cancer diagnostics and PVSA care.
Read More
Veracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.
Read More
A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
Read More
Decipher Prostate Genomic Classifier data is included in a new SEER Program database, enabling the study of prostate cancer outcomes.
Read More
Lynx Dx announced at-home availability of a urine-based prostate cancer test that eliminates the need for a digital rectal exam.
Read More
A new study validated a urine test that offers a less invasive, more accurate alternative to traditional prostate cancer screening.
Read More
A review found gaps remain for genomic classifier tests for their cost-effectiveness, clinical utility, and impact on diverse populations.
Read More
The AR-ctDETECT test identifies circulating tumor DNA in advanced prostate cancer patients, providing critical insights for prognostication.
Read More
A genetic variant in the PSA gene may help improve prostate cancer diagnostics by distinguishing between aggressive and non-aggressive types.
Read More
A study shows that measuring CTCs at the time of metastatic prostate cancer diagnosis can predict survival and guide treatment decisions.
Read More
A new prostate cancer screening method could help better predict which patients need to undergo a biopsy, reducing unnecessary procedures.
Read More
GRAIL’s Galleri multi-cancer early detection test demonstrates strong performance in preferentially identifying aggressive prostate cancers.
Read More
A newly discovered class of RNA molecules in extracellular vesicles could serve as biomarkers for non-invasive cancer diagnosis.
Read More
A retrospective study shows that combining risk markers, MRI evaluation, and AI can more accurately predict prostate cancer risk.
Read More
Studies indicate men with BRCA1 and BRCA2 mutations face significant cancer risks, prompting new national screening guidelines.
Read More